Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC000459 in grass pollen–induced allergic rhinitis (Vienna Challenge Chamber)
2007-000017-11Phase 2Terminated
- Sponsor
- Oxagen
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of timapiprant in allergic rhinitis (AR) (2 arms), sponsored by Oxagen. Primary endpoints: Efficacy response to allergen challenge and Safety outcomes. Started Feb 2007; status: terminated.
02
Drugs
timapiprant
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2007-000017-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000017-11.